The clinical significance of statins-macrolides interaction: comprehensive review of in vivo studies, case reports, and population studies

References

• Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19(1):117–125. doi:10.1111/j.1472-8206.2004.00299.x15660968
   PubMed Web of Science ®Google Scholar
• Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5(4):378–387. doi:10.1111/j.1582-4934.2001.tb00172.x12067471
   PubMed Web of Science ®Google Scholar
• Naci H, Brugts JJ, Fleurence R, Tsoi B, Toor H, Ades AE. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials. Eur J Prev Cardiol. 2013;20(4):641–657. doi:10.1177/204748731348043523447425
   PubMed Web of Science ®Google Scholar
• Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science (New York, NY). 2001;292(5519):1160–1164. doi:10.1126/science.1059344
   Google Scholar
• Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH. Biotransformation of pravastatin sodium in humans. Drug Metab Dispos. 1991;19(4):740–748.1680649
   PubMed Web of Science ®Google Scholar
• Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther. 2003;25(11):2822–2835.14693307
   PubMed Web of Science ®Google Scholar
• Saito Y. Pitavastatin: an overview. Atheroscler Suppl. 2011;12(3):271–276. doi:10.1016/S1567-5688(11)70886-822152281
   PubMed Web of Science ®Google Scholar
• Elsby R, Hilgendorf C, Fenner K. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it’s not just about OATP1B1. Clin Pharmacol Ther. 2012;92(5):584–598. doi:10.1038/clpt.2012.16323047648
   PubMed Web of Science ®Google Scholar
• Henwood JM, Heel RC. Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs. 1988;36(4):429–454. doi:10.2165/00003495-198836040-000033069436
   PubMed Web of Science ®Google Scholar
• Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol. 2001;57(5):357–364.11599653
   PubMed Web of Science ®Google Scholar
• Beauduy CE, Winston LG. Tetracyclines, macrolides, clindamycin, chloramphenicol, streptogramins, & oxazolidinones In: Katzung BG, editor. Basic & Clinical Pharmacology, 14e. New York, NY: McGraw-Hill Education; 2017: 815–825.
   Google Scholar
• Shi J, Montay G, Bhargava VO. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet. 2005;44(9):915–934. doi:10.2165/00003088-200544090-0000316122280
   PubMed Web of Science ®Google Scholar
• Zuckerman JM, Qamar F, Bono BR. Review of Macrolides (Azithromycin, Clarithromycin), Ketolids (Telithromycin) and Glycylcyclines (Tigecycline). Med Clin. 2011;95(4):761–791. doi:10.1016/j.mcna.2011.03.012
   Web of Science ®Google Scholar
• Parkinson A, Ogilvie BW, Buckley DB, Kazmi F, Czerwinski M, Parkinson O. Biotransformation of xenobiotics In: Casarett and Doull’s Toxicology: The Basic Science of Poisons, 8e. Curtis D. Klaassen. New York, NY: McGraw-Hill Education; 2012: 185–366.
   Google Scholar
• Hirota T, Ieiri I. Drug-drug interactions that interfere with statin metabolism. Expert Opin Drug Metab Toxicol. 2015;11(9):1435–1447. doi:10.1517/17425255.2015.105614926058399
   PubMed Web of Science ®Google Scholar
• Pinto AG, Wang YH, Chalasani N, et al. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther. 2005;77(3):178–188. doi:10.1016/j.clpt.2004.10.00215735612
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Ther. 1998;64(3):278–285. doi:10.1016/S0009-9236(98)90176-X9757151
   PubMed Web of Science ®Google Scholar
• Ito K, Ogihara K, Kanamitsu S, Itoh T. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos. 2003;31(7):945–954. doi:10.1124/dmd.31.7.94512814973
   PubMed Web of Science ®Google Scholar
• Polasek TM, Miners JO. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. Eur J Clin Pharmacol. 2006;62(3):203–208. doi:10.1007/s00228-005-0091-x16416302
   PubMed Web of Science ®Google Scholar
• Quinney SK, Malireddy SR, Vuppalanchi R, et al. Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin. Eur J Clin Pharmacol. 2013;69(3):439–448. doi:10.1007/s00228-012-1339-x22777148
   PubMed Web of Science ®Google Scholar
• Zhou S, Yung Chan S, Cher Goh B, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44(3):279–304. doi:10.2165/00003088-200544030-0000515762770
   PubMed Web of Science ®Google Scholar
• Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet. 1998;35(5):361–390. doi:10.2165/00003088-199835050-000039839089
   PubMed Web of Science ®Google Scholar
• Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics. 2007;8(7):787–802. doi:10.2217/14622416.8.7.78718240907
   PubMed Web of Science ®Google Scholar
• Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005;15(7):513–522.15970799
   PubMed Web of Science ®Google Scholar
• Jiang F, Choi JY, Lee JH, et al. The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition. Pharmacogenomics. 2017;18(5):459–469. doi:10.2217/pgs-2016-019928350522
   PubMed Web of Science ®Google Scholar
• Menochet K, Kenworthy KE, Houston JB, Galetin A. Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes. Drug Metab Dispos. 2012;40(9):1744–1756. doi:10.1124/dmd.112.04619322665271
   PubMed Web of Science ®Google Scholar
• Lau YY, Huang Y, Frassetto L, Benet LZ. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 2007;81(2):194–204. doi:10.1038/sj.clpt.610003817192770
   PubMed Web of Science ®Google Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther. 2006;80(4):356–366. doi:10.1016/j.clpt.2006.06.01017015053
   PubMed Web of Science ®Google Scholar
• Chang JH, Zhang X, Messick K, et al. Unremarkable impact of Oatp inhibition on the liver concentration of fluvastatin, lovastatin and pitavastatin in wild-type and Oatp1a/1b knockout mouse. Xenobiotica. 2018;49:1–9.
   Web of Science ®Google Scholar
• Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007;82(6):726–733. doi:10.1038/sj.clpt.610022017473846
   PubMed Web of Science ®Google Scholar
• Deng JW, Song IS, Shin HJ, et al. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008;18(5):424–433. doi:10.1097/FPC.0b013e3282fb02a318408565
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Chu X, Evers R, et al. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin. Br J Clin Pharmacol. 2014;78(3):587–598. doi:10.1111/bcp.1237724617605
   PubMed Web of Science ®Google Scholar
• Kunze A, Huwyler J, Camenisch G, Poller B. Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data. Drug Metab Dispos. 2014;42(9):1514–1521. doi:10.1124/dmd.114.05841224989890
   PubMed Web of Science ®Google Scholar
• Seithel A, Eberl S, Singer K, et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos. 2007;35(5):779–786. doi:10.1124/dmd.106.01440717296622
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006;34(7):1229–1236. doi:10.1124/dmd.106.00929016595711
   PubMed Web of Science ®Google Scholar
• Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther. 2008;84(4):457–461. doi:10.1038/clpt.2008.2519238649
   PubMed Web of Science ®Google Scholar
• Hochman JH, Pudvah N, Qiu J, et al. Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res. 2004;21(9):1686–1691.15497697
   PubMed Web of Science ®Google Scholar
• Umeyama Y, Fujioka Y, Okuda T. Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information. Xenobiotica. 2014;44(12):1135–1144. doi:10.3109/00498254.2014.92895824937160
   PubMed Web of Science ®Google Scholar
• Holtzman CW, Wiggins BS, Spinler SA. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy. 2006;26(11):1601–1607. doi:10.1592/phco.26.11.160117064205
   PubMed Web of Science ®Google Scholar
• Mao Q, Unadkat JD. Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport–an update. Aaps J. 2014;17(1):65–82. doi:10.1208/s12248-014-9668-625236865
   PubMed Web of Science ®Google Scholar
• Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2009;86(2):197–203. doi:10.1038/clpt.2009.7919474787
   PubMed Web of Science ®Google Scholar
• Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics. 2009;10(10):1617–1624. doi:10.2217/pgs.09.8519842935
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kusuhara H, Watanabe T, et al. Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011;39(6):1031–1038. doi:10.1124/dmd.110.03612921383204
   PubMed Web of Science ®Google Scholar
• Niemi M, Arnold KA, Backman JT, et al. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet Genomics. 2006;16(11):801–808. doi:10.1097/01.fpc.0000230422.50962.9117047488
   PubMed Web of Science ®Google Scholar
• Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology. 2004;126(1):322–342.14699511
   PubMed Web of Science ®Google Scholar
• Bi YA, Qiu X, Rotter CJ, et al. Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin. Biopharm Drug Dispos. 2013;34(8):452–461. doi:10.1002/bdd.186123996477
   PubMed Web of Science ®Google Scholar
• Khan FY. Rhabdomyolysis: a review of the literature. Neth J Med. 2009;67(9):272–283.19841484
   PubMed Web of Science ®Google Scholar
• Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol. 2004;94(9):1140–1146. doi:10.1016/j.amjcard.2004.07.08015518608
   PubMed Web of Science ®Google Scholar
• Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther. 1998;64(2):177–182. doi:10.1016/S0009-9236(98)90151-59728898
   PubMed Web of Science ®Google Scholar
• KETEX (telithromycin) tablets [Prescribing Information-drug Interactions]. Bridgewater, NJ 08807: Sanofi-aventis U.S. LLC; 2015.
   Google Scholar
• Kaleem Z, Khan JA, Mushtaq Z, Altaf S, Javed I. Assessment of potential interaction between simvastatin and clarithromycin in healthy adult male subjects. Pak J Pharm Sci. 2018;31(3):801–806.29716858
   PubMed Web of Science ®Google Scholar
• Siedlik PH, Olson SC, Yang BB, Stern RH. Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol. 1999;39(5):501–504.10234598
   PubMed Web of Science ®Google Scholar
• LIPITOR (atorvastatin) tablets [prescribing information]. NY, NY 10017: Parke-Davis-Pfizer Inc; 2009.
   Google Scholar
• Amsden GW, Kuye O, Wei GC. A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J Clin Pharmacol. 2002;42(4):444–449.11936570
   PubMed Web of Science ®Google Scholar
• Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol. 2003;59(1):51–56. doi:10.1007/s00228-003-0573-712682802
   PubMed Web of Science ®Google Scholar
• LIVALO (pitavastatin) prescribing information (drug interactions); 2016 Available from: https://www.kowapharma.com/documents/LIVALO_PI_CURRENT.pdf. Accessed 512, 2018.
   Google Scholar
• Torres PA, Helmstetter JA, Kaye AM, Kaye AD. Rhabdomyolysis: pathogenesis, diagnosis, and treatment. Ochsner J. 2015;15(1):58–69.25829882
   PubMed Web of Science ®Google Scholar
• Davidson MH, Clark JA, Glass LM, Kanumalla A. Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol. 2006;97(8a):32c–43c. doi:10.1016/j.amjcard.2005.12.008
   PubMed Web of Science ®Google Scholar
• Hill FJ, McCloskey SJ, Sheerin N. From a fish tank injury to hospital haemodialysis: the serious consequences of drug interactions. BMJ Case Rep. 2015;2015:bcr2015209961. doi:10.1136/bcr-2015-209961
   PubMedGoogle Scholar
• Fallah A, Deep M, Smallwood D, Hughes P. Life-threatening rhabdomyolysis following the interaction of two commonly prescribed medications. Australas Med J. 2013;6(3):112–114. doi:10.4066/AMJ.2013.161623589735
   PubMedGoogle Scholar
• Azmi HM, Fahad S, Kumar VA. Lovastatin-erythromycin induced myositis: case report and possible mechanism. J Pharm Pharm. 2015;1(1):30–32. doi:10.5530/jppcm.2015.1.7
   Google Scholar
• Grunden JW, Fisher KA. Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. Ann Pharmacother. 1997;31(7–8):859–863. doi:10.1177/1060028097031007109220046
   PubMed Web of Science ®Google Scholar
• Kahri AJ, Valkonen MM, Vuoristo MK, Pentikäinen PJ. Rhabdomyolysis associated with concomitant use of simvastatin and clarithromycin. Ann Pharmacother. 2004;38(4):719. doi:10.1345/aph.1D243
   PubMed Web of Science ®Google Scholar
• Spach DH, Bauwens JE, Clark CD, Burke WG. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med. 1991;154(2):213–215.2006579
   PubMedGoogle Scholar
• Alreja G, Inayatullah S, Goel S, Braden G. Rhabdomyolysis caused by an unusual interaction between azithromycin and simvastatin. J Cardiovasc Dis Res. 2012;3(4):319–322. doi:10.4103/0975-3583.10272023233778
   PubMedGoogle Scholar
• Wagner J, Suessmair C, Pfister HW. Rhabdomyolysis caused by co-medication with simvastatin and clarithromycin. J Neurol. 2009;256(7):1182–1183. doi:10.1007/s00415-009-5078-619252767
   PubMed Web of Science ®Google Scholar
• Page SR, Yee KC. Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin. Intern Med J. 2014;44(7):690–693. doi:10.1111/imj.1246425041770
   PubMed Web of Science ®Google Scholar
• Lee AJ, Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother. 2001;35(1):26–31. doi:10.1345/aph.1017711197581
   PubMed Web of Science ®Google Scholar
• Molden E, Andersson KS. Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients. Pharmacotherapy. 2007;27(4):603–607. doi:10.1592/phco.27.4.60317381388
   PubMed Web of Science ®Google Scholar
• Nguyen KA, Li L, Lu D, et al. A comprehensive review and meta-analysis of risk factors for statin-induced myopathy. Eur J Clin Pharmacol. 2018;74(9):1099–1109. doi:10.1007/s00228-018-2482-929785580
   PubMed Web of Science ®Google Scholar
• Mendes P, Robles PG, Mathur S. Statin-induced rhabdomyolysis: a comprehensive review of case reports. Physiother Can. 2014;66(2):124–132. doi:10.3138/ptc.2012-6524799748
   PubMed Web of Science ®Google Scholar
• Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol. 2006;97(8a):61c–68c. doi:10.1016/j.amjcard.2005.12.01116377285
   PubMed Web of Science ®Google Scholar
• Slobodnick A, Shah B, Pillinger MH, Krasnokutsky S. Colchicine: old and new. Am J Med. 2015;128(5):461–470. doi:10.1016/j.amjmed.2014.12.01025554368
   PubMed Web of Science ®Google Scholar
• Davis MW, Wason S, Digiacinto JL. Colchicine-antimicrobial drug interactions: what pharmacists need to know in treating gout. Consult Pharm. 2013;28(3):176–183. doi:10.4140/TCP.n.2013.17623462027
   PubMedGoogle Scholar
• Nishio S, Watanabe H, Kosuge K, Uchida S, Hayashi H, Ohashi K. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res. 2005;28(3):223–227. doi:10.1291/hypres.28.22316097365
   PubMed Web of Science ®Google Scholar
• Pan Y, Chothe PP, Swaan PW. Identification of novel Breast Cancer Resistance Protein (BCRP) Inhibitors by virtual screening. Mol Pharm. 2013;10(4):1236–1248. doi:10.1021/mp300547h23418667
   PubMed Web of Science ®Google Scholar
• Strandell J, Bate A, Hagg S, Edwards IR. Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction. Br J Clin Pharmacol. 2009;68(3):427–434. doi:10.1111/j.1365-2125.2009.03473.x19740401
   PubMed Web of Science ®Google Scholar
• Rowan C, Brinker AD, Nourjah P, et al. Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. Pharmacoepidemiol Drug Saf. 2009;18(4):301–309. doi:10.1002/pds.171119206087
   PubMed Web of Science ®Google Scholar
• Rowan CG, Brunelli SM, Munson J, et al. Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in the health improvement network. Pharmacoepidemiol Drug Saf. 2012;21(5):494–506. doi:10.1002/pds.319922422642
   PubMed Web of Science ®Google Scholar
• Patel AM, Shariff S, Bailey DG, et al. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. Ann Intern Med. 2013;158(12):869–876. doi:10.7326/0003-4819-158-12-201306180-0000423778904
   PubMed Web of Science ®Google Scholar
• Li DQ, Kim R, McArthur E, et al. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. Can Med Assoc J. 2015;187(3):174–180. doi:10.1503/cmaj.14095025534598
   PubMed Web of Science ®Google Scholar
• Mesgarpour B, Gouya G, Herkner H, Reichardt B, Wolzt M. A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death. Lipids Health Dis. 2015;14:131. doi:10.1186/s12944-015-0134-y26497728
   PubMed Web of Science ®Google Scholar
• Kolovou V, Bilianou H, Kolovou G. Safe use of statins: focus on muscle toxicity. Clin Lipidol. 2016;11(1):16–22.
   Google Scholar
• Chang C-H, Kusama M, Ono S, Sugiyama Y, Orii T, Akazawa M. Assessment of statin-associated muscle toxicity in Japan: a cohort study conducted using claims database and laboratory information. BMJ Open. 2013;3(4):e002040. doi:10.1136/bmjopen-2012-002040
   PubMed Web of Science ®Google Scholar
• New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury FDA Drug Safety Communication. August 6th, 2011 Available from: https://wayback.archive-it.org/7993/20170112031805/http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm. Accessed December 11, 2018.
   Google Scholar
• ZOCOR (simvastatin) tablets [prescribing information]. Cramlington, Northumberland, UK NE23 3JU: Merck Sharp & Dohme Ltd; 2010.
   Google Scholar
• Lovastatin - FDA prescribing information, side effects and uses. Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA; 2018 Available from: https://www.drugs.com/pro/lovastatin.html. Accessed January 18, 2019.
   Google Scholar
• PRAVACHOL (Pravastatin) tablets [Prescribing Information]. Princeton, New Jersey 08543 USA; Bristol-Myers Squibb Company; 2014.
   Google Scholar
• Garcia MJ, Reinoso RF, Sanchez Navarro A, Prous JR. Clinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol. 2003;25(6):457–481.12949632
   PubMed Web of Science ®Google Scholar